Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Nov 10, 2017 at 10:40 AM EST

Short Sellers Grow More Selective on Major Biotechs

The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech…

Lee Jackson | Nov 10, 2017 at 10:15 AM EST

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar…

Chris Lange | Nov 9, 2017 at 12:05 PM EST

Sage Therapeutics Wins Big in Depression Trial

Sage Therapeutics shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum…

Chris Lange | Nov 9, 2017 at 9:20 AM EST

Why Otonomy Shares Are Skyrocketing

Otonomy reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage…

Chris Lange | Nov 8, 2017 at 8:45 AM EST

Voyager Therapeutics Gears Up for Secondary Offering

Voyager Therapeutics has seen a decent year for its shares and it seems now is the best time to cash…

Chris Lange | Nov 7, 2017 at 12:20 PM EST

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the…

Paul Ausick | Nov 7, 2017 at 8:30 AM EST

Valeant Earnings Soar on Tax Benefit

Drug maker Valeant got a big profit boost from a one-time tax benefit and the company also boosted its EPS…

Chris Lange | Nov 6, 2017 at 11:05 AM EST

Why Solid CVS Health Earnings Are Not Enough

CVS Health reported solid third-quarter financial results before the markets opened on Monday, but that was not enough for investors.

Paul Ausick | Nov 6, 2017 at 8:05 AM EST

Why Mylan Shares Were Bouncing Around After Q3 Earnings

Pharmaceutical maker Mylan missed analysts' consensus estimate for earnings and revenue. Additional guidance is mixed, causing shares first to fall…

Chris Lange | Nov 3, 2017 at 11:10 AM EDT

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a…

Paul Ausick | Nov 3, 2017 at 9:40 AM EDT

ImmunoGen Shares Collapse After Huge Miss on Profits, Revenues

Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating…

Chris Lange | Nov 2, 2017 at 11:25 AM EDT

Intellia Therapeutics Gears Up for Secondary Offering

Intellia Therapeutics saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering.

Chris Lange | Nov 2, 2017 at 9:55 AM EDT

Teva Earnings Send Shares to New Low Not Seen in Over a Decade

These quarterly numbers are another black eye for Teva Pharmaceutical, sending shares to a low not seen since 2002.

Chris Lange | Oct 31, 2017 at 11:25 AM EDT

Can This FDA Approval Keep Lifting Geron?

Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower…

Chris Lange | Oct 31, 2017 at 10:15 AM EDT

Pfizer Earnings Not Enough for Investors

When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to…

1 … 150 151 152 153 154 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Grow More Selective on Major Biotechs

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Sage Therapeutics Wins Big in Depression Trial

Why Otonomy Shares Are Skyrocketing

Voyager Therapeutics Gears Up for Secondary Offering

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Valeant Earnings Soar on Tax Benefit

Why Solid CVS Health Earnings Are Not Enough

Why Mylan Shares Were Bouncing Around After Q3 Earnings

Sarepta Takes Another Big Step Forward With DMD Treatment

ImmunoGen Shares Collapse After Huge Miss on Profits, Revenues

Intellia Therapeutics Gears Up for Secondary Offering

Teva Earnings Send Shares to New Low Not Seen in Over a Decade

Can This FDA Approval Keep Lifting Geron?

Pfizer Earnings Not Enough for Investors

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Grow More Selective on Major Biotechs

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

Sage Therapeutics Wins Big in Depression Trial

Why Otonomy Shares Are Skyrocketing

Voyager Therapeutics Gears Up for Secondary Offering

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Valeant Earnings Soar on Tax Benefit

Why Solid CVS Health Earnings Are Not Enough

Why Mylan Shares Were Bouncing Around After Q3 Earnings

Sarepta Takes Another Big Step Forward With DMD Treatment

ImmunoGen Shares Collapse After Huge Miss on Profits, Revenues

Intellia Therapeutics Gears Up for Secondary Offering

Teva Earnings Send Shares to New Low Not Seen in Over a Decade

Can This FDA Approval Keep Lifting Geron?

Pfizer Earnings Not Enough for Investors

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how